Case series of de novo occurrence of Graves’ disease following thermal ablation for benign thyroid nodules: an uncommon event that should be considered
European Thyroid Journal · 2025
DOI: 10.1530/etj-25-0205 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Thyroid Journal, 2025. Verfasst von Marsida Teliti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Graves Disease, Thyroid Nodule, Radiofrequency Ablation, Ablation Techniques. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Thermal ablation (TA), including radiofrequency (RFA) and microwave ablation (MWA), is a widely used, minimally invasive alternative to surgery for benign thyroid nodules. While transient, self-limited thyrotoxicosis is a recognized effect of the procedure, the onset of Graves’ disease (GD) post-TA remains exceedingly rare and poorly characterized. Case reports We report three cases of new-onset GD occurring 3–10 months after RFA or MWA, identified among more than 500 patients treated at our tertiary care Endocrinology Unit. All patients were female and had undergone TA for cytologically benign nodules. Two had a documented history of thyroid autoimmunity. At diagnosis, all three exhibited suppressed TSH, elevated thyroid hormone levels, and positive anti-TSH receptor antibodies (TRAb). None had been tested for TRAb before treatment. One case occurred during pregnancy and was managed with propylthiouracil; the others received antithyroid treatment with methimazole.
Conclusion
Although rare, GD may develop following TA, likely through immune activation triggered by thyroid tissue injury in genetically predisposed individuals. Routine TRAb screening before TA is not currently justified; however, clinical awareness is essential to distinguish transient post-ablation thyrotoxicosis from true GD and to ensure timely initiation of antithyroid therapy when appropriate. Despite these rare cases, the overall incidence remains very low, confirming the excellent safety profile of TA for benign thyroid nodules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
- Unit of Endocrinology and Metabolism, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
ORCID-Profile: Flavia Magri, Mario Rotondi
Zitieren
APA
Teliti, M., Grillini, B., Chiardi, I., Magri, F., Coperchini, F., Croce, L., Rotondi, M., & Chytiris, S. (2025). Case series of de novo occurrence of Graves’ disease following thermal ablation for benign thyroid nodules: an uncommon event that should be considered. European Thyroid Journal. https://doi.org/10.1530/etj-25-0205
Vancouver
Teliti M, Grillini B, Chiardi I, Magri F, Coperchini F, Croce L, et al. Case series of de novo occurrence of Graves’ disease following thermal ablation for benign thyroid nodules: an uncommon event that should be considered. European Thyroid Journal. 2025. doi:10.1530/etj-25-0205
BibTeX
@article{Teliti2025,
author = {Teliti, Marsida and Grillini, Beatrice and Chiardi, Isabella and Magri, Flavia and Coperchini, Francesca and Croce, Laura and Rotondi, Mario and Chytiris, Spyridon},
title = {Case series of de novo occurrence of Graves’ disease following thermal ablation for benign thyroid nodules: an uncommon event that should be considered},
journal = {European Thyroid Journal},
year = {2025},
doi = {10.1530/etj-25-0205}
}
EUVIMED